文献速递免疫规划卫生政策与健康促进

日本疫苗数据库的建立与应用:疫苗有效性、网络与通用安全性(VENUS)研究

Development and application of a Japanese vaccine database for comparative assessments in the post-authorization phase: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.
PubMed 文献 · Vaccine · 2022-09-09

以2018/2019季老年人流感疫苗安全性试点分析为例,48,723名接种者与48,723名未接种者匹配,唯一共同不良事件为贝尔麻痹,调整发病率比为1.21(95%CI 0.48-3.07)。

要点

  • 2018财年数据含853,016人,中位年龄70岁(四分位距52-79)。
  • 试点中贝尔麻痹调整发病率比1.21(95%CI 0.48-3.07),未达统计学显著。

核心结论

  • VENUS研究是日本首个可对全年龄组大规模接种与未接种者进行比较评估的医疗数据平台。
  • 目前正努力增加参与市町村数量并生成疫苗有效性与安全性证据。

研究设计与样本

  • 通过链接公共保险参保人理赔数据与参与市町村的疫苗接种记录建立数据库。
  • 试点分析为2018/2019季单一市町村≥65岁老年人流感疫苗安全性评估,匹配48,723名接种者与48,723名未接种者。

主要发现

  • 2018财年数据包含853,016人(男性363,079人,女性489,937人),中位年龄70岁(四分位距52-79)。
  • 试点中两组唯一共同发生的不良事件为贝尔麻痹,调整发病率比为1.21(95%CI 0.48-3.07)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Japan currently lacks a data platform that can support quantitative assessments of the causal relationships between vaccines and adverse events. This study describes the development and application of the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study to facilitate such assessments. METHODS: A database was created by linking public insurance enrollees' claims data with vaccination records acquired from participating municipalities. To provide an overview of the study data, we produced descriptive statistics of sex, age, and vaccinations. We also conducted a pilot study using the database to assess influenza vaccine safety during the 2018/2019 season among older persons (≥65 years) residing in a single municipality. RESULTS: Our database was created using data from approximately 1.12 million individuals in 7 municipalities between 2013 and 2020. The data during fiscal year 2018 included 853,016 individuals (male: 363,079, female: 489,937) with a median age of 70 years (interquartile range: 52-79). We obtained information on 17 vaccine types, including the pneumococcal vaccine and influenza vaccine. In the pilot study, we analyzed 48,723 vaccinated persons matched with 48,723 unvaccinated persons. The only adverse event that occurred in both groups was Bell's palsy, which had an adjusted incidence rate ratio of 1.21 (95 % confidence interval: 0.48-3.07). CONCLUSIONS: The VENUS Study is Japan's first healthcare data platform that enables comparative assessments of vaccinated and unvaccinated persons in large samples covering all age groups. Efforts are underway to increase the number of participating municipalities and to generate evidence on vaccine effectiveness and safety.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ishiguro C, Mimura W, Murata F, et al. Development and application of a Japanese vaccine database for comparative assessments in the post-authorization phase: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. Vaccine. 2022. PMID: 36096969. doi:10.1016/j.vaccine.2022.08.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。